Glenmark Pharmaceuticals Monday said it has received final approval from the US health regulator for antiplatelet agents Aspirin and extended-release Dipyridamole capsules. The approved product is a generic version of Aggrenox capsules of Boehringer Ingelheim Pharmaceuticals Inc. Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Aspirin and extended-release Dipyridamole capsules in the strength of 25 mg/200 mg, the company said in a BSE filing. Citing IQVIA sales data, Glenmark said, the Aggrenox capsules, 25 mg/200 mg market achieved annual sales of approximately USD 165.6 million in the 12-month period ended March 2019. The company said its current portfolio consists of 155 products authorised for distribution in the US and 58 Abbreviated New Drug Application (ANDA's) pending approval with the USFDA. Shares of Glenmark Pharma were trading 0.03 per cent higher at Rs 559.20 apiece on the BSE.
from Latest News http://bit.ly/2QpFbOl
https://ift.tt/eA8V8J http://bit.ly/2SdCH5P
Home
Business
Business News
Business Standard
Latest News
Glenmark Pharma receives final approval from USFDA for antiplatelet drug
Monday, May 27, 2019
Related Posts:
No cap on applications for Indian passport renewal in Abu Dhabi from July 15The Indian Embassy has decided to remove all restrictions on passport … Read More
United Airlines sending layoff notices to nearly half of its US employeesIn the clearest signal yet of how deeply the virus outbreak is hurting… Read More
Syllabus reduction by up to 30% a one-time measure only, clarifies CBSEA day after revising the syllabus for classes 9 to 12 for 2020-21 acad… Read More
Galwan row: China retreated as India put diplomatic pressure, says VK SinghUnion Minister VK Singh has said that India put diplomatic pressure on… Read More
0 comments: